[go: up one dir, main page]

WO2019088658A1 - Anticorps à double ciblage ciblant le scf et la galectine-1 et son utilisation - Google Patents

Anticorps à double ciblage ciblant le scf et la galectine-1 et son utilisation Download PDF

Info

Publication number
WO2019088658A1
WO2019088658A1 PCT/KR2018/013016 KR2018013016W WO2019088658A1 WO 2019088658 A1 WO2019088658 A1 WO 2019088658A1 KR 2018013016 W KR2018013016 W KR 2018013016W WO 2019088658 A1 WO2019088658 A1 WO 2019088658A1
Authority
WO
WIPO (PCT)
Prior art keywords
seq
antibody
scf
galectin
angiogenesis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/013016
Other languages
English (en)
Korean (ko)
Inventor
박상규
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Comeworth Pharma Inc
Original Assignee
Comeworth Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180127615A external-priority patent/KR102131898B1/ko
Application filed by Comeworth Pharma Inc filed Critical Comeworth Pharma Inc
Priority to CN201880070926.4A priority Critical patent/CN111295393B/zh
Priority to EP18873464.4A priority patent/EP3712169A4/fr
Priority to US16/760,513 priority patent/US11377489B2/en
Priority to JP2020543441A priority patent/JP6922098B2/ja
Publication of WO2019088658A1 publication Critical patent/WO2019088658A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Definitions

  • the present invention relates to a dual target antibody targeting SCF (Stem Cell Factor) and galectin-1 (Galectin-1) and a composition for preventing or treating angiogenesis-related diseases comprising the same.
  • SCF stem cell factor
  • VEGF Vascular Endothelial Growth Factor
  • Angiogenesis refers to the generation of new microvessels from existing blood vessels that are already present by the vasogenic factor in the body. When cells grow to a certain extent, they secrete substances that stimulate angiogenesis, and when secreted too much, secrete substances that inhibit it. Feedback is used to maintain the balance of blood vessel production.
  • Abnormal angiogenesis changes the blood vessels and increases the permeability, causing diseases that cause bleeding. Examples include age-related macular degeneration, diabetic retinopathy, choroidal neovascularization, glaucoma retinitis igmentosa, retinopathy od prematurity, glaucoma diseases such as glaucoma, corneal dystrophy, retinoschisis, rheumatoid arthritis, psoriasis, metastasis, and delayed wound healing occur.
  • the angiogenesis in the cornea of the above-mentioned diseases inhibits the transparency of the eyeball, resulting in loss of visual acuity.
  • abnormal blood vessels are generated, resulting in exudation of blood, To induce blindness through. Therefore, it is desirable that the angiogenesis in the eye is not a desirable phenomenon, but it is desirable to be suppressed as much as possible.
  • diseases caused by abnormal angiogenesis can increase the therapeutic effect of the disease only by inhibiting the angiogenesis.
  • angiogenesis inhibitors are activated against the activity of angiogenic factors required for angiogenesis.
  • Naturally occurring angiogenesis inhibitors in the body are less toxic and can be used to inhibit pathological angiogenesis, and many related drugs are under development.
  • the present inventors have found that SCF (stem cell factor) and galectin-1 promote angiogenesis, whereas inhibiting the expression of SCF and galectin-
  • the present inventors have completed the present invention by producing a double target antibody capable of simultaneously neutralizing SCF and galectin-1.
  • It is still another object of the present invention to provide a pharmaceutical composition for preventing or treating angiogenesis-related diseases comprising a double-target antibody that specifically binds to SCF and galectin-1.
  • the present invention provides a light chain CDR1 comprising an amino acid sequence of SEQ ID NO: 1, a light chain CDR2 represented by an amino acid sequence of SEQ ID NO: 2, and a light chain CDR3 represented by an amino acid sequence of SEQ ID NO: 3 Light chain variable region; And a heavy chain variable region comprising the heavy chain CDR1 represented by the amino acid sequence of SEQ ID NO: 4, the heavy chain CDR2 represented by the amino acid sequence of SEQ ID NO: 5, and the heavy chain CDR3 represented by the amino acid sequence of SEQ ID NO: 6. (Stem Cell Factor) and galectin-1 (Galectin-1).
  • the present invention also provides a method for producing a light chain CDR1 comprising the light chain CDR1 represented by SEQ ID NO: 1, the light chain CDR2 represented by SEQ ID NO: 2, and the light chain CDR3 represented by SEQ ID NO: 3 by the nucleotide sequence of SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: DNA encoding a light chain variable region comprising; And a heavy chain variable region comprising the nucleotide sequence of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, which respectively encode the heavy chain CDR1 of SEQ ID NO: 4, the heavy chain CDR2 of SEQ ID NO: 5 and the heavy chain CDR3 of SEQ ID NO: DNA coding region; A DNA encoding a double-target antibody that specifically binds to SCF and galectin-1.
  • the present invention also provides a vector comprising the DNA and a cell transformed with the vector.
  • the present invention also provides a pharmaceutical composition for preventing or treating an angiogenesis-related disease comprising a double-target antibody that specifically binds to SCF and galectin-1.
  • the present invention also relates to a method for screening for a compound that specifically binds to SCF and galectin-1 to a subject in need thereof; And a method for preventing or treating an angiogenesis-related disease.
  • the present invention also provides a composition for simultaneous detection of SCF and galectin-1 comprising a double-target antibody specifically binding to SCF and galectin-1.
  • the present invention relates to a method for preventing or treating an angiogenesis-related disease comprising a human monoclonal antibody derived from a human monoclonal antibody, which is capable of effectively inhibiting neovascularization by simultaneously neutralizing SCF and galectin-1 involved in angiogenesis, A pharmaceutical composition is provided.
  • the dual target antibody according to the present invention can simultaneously prevent or treat an angiogenesis-related disease that causes hemorrhage because blood vessels are changed due to abnormal angiogenesis by simultaneously neutralizing two targets involved in angiogenesis.
  • FIG. 1 shows a total of 9 monoclonal antibodies 3C6, 3A2, 3C3, 3A4, 3E7, 3C8, 3C4, 3F7 and 3F3 selected by enzyme immunoassay.
  • FIG. 2 is a graph showing inhibition of tube formation of vascular endothelial cells of HUVEC (vascular endothelial cells) by treating all 9 monoclonal antibodies of the present invention.
  • Fig. 3 is a graph showing the result of electrophoresis of the light chain domain DNA in the 3C4 antibody variable region amplified by PCR on 1% agarose gel.
  • FIG. 4 is a graph showing the results of electrophoresis of the heavy chain domain DNA among 3C4 antibody variable regions amplified by PCR on 1% agarose gel.
  • FIG. 4 is a graph showing the results of electrophoresis of the heavy chain domain DNA among 3C4 antibody variable regions amplified by PCR on 1% agarose gel.
  • Fig. 5 is a diagram showing the base sequence, amino acid sequence and CDR region thereof of the 3C4 antibody light chain region.
  • 6 is a diagram showing the base sequence, amino acid sequence and CDR region thereof of the 3C4 antibody heavy chain region.
  • FIG. 8 is a graph showing the results of SPR (surface plasmon resonance) for confirming the SCF binding ability of a human 3C4 antibody according to the present invention.
  • FIG. 9 is a graph showing the ability of the human 3C4 antibody according to the present invention to inhibit the tube formation of vascular endothelial cells (HUVEC).
  • FIG. 10 is a graph showing the results of c-kit phosphorylation inhibition assay of the human 3C4 antibody according to the present invention.
  • FIG. 11 is a graph showing the results of protein microarray analysis using a human 3C4 antibody according to the present invention.
  • FIG. 13 is a graph showing the results of SPR (surface plasmon resonance) for confirming galectin-1 binding ability of human 3C4 antibody according to the present invention.
  • FIG. 14 is a graph showing the ability of the human 3C4 antibody according to the present invention to inhibit the formation of vascular endothelial cells.
  • FIG. 15 is a graph showing the ability of human 3C4 antibody according to the present invention to inhibit cell proliferation by galectin-1 (A) and SCF (B).
  • FIG. 16 is a graph showing the ability of each antibody to inhibit the tube formation of vascular endothelial cells in order to compare the neutralization ability of a human 3C4 antibody and a commercially available SCF antibody according to the present invention.
  • the present inventors first produced a double-target antibody capable of preventing or treating the above-mentioned diseases by inhibiting angiogenesis in angiogenesis-related diseases.
  • the dual target antibody may be a "polyclonal” or "monoclonal” antibody, but a monoclonal antibody is more preferable.
  • a monoclonal antibody refers to an antibody obtained from a substantially homogeneous population of antibodies, i.e., the individual antibodies that make up this population are identical except for possible naturally occurring mutations that may be present in minor amounts.
  • Monoclonal antibodies are highly specific for single antigenic sites. Moreover, contrary to polyclonal antibodies comprising different antibodies to different epitopes, each monoclonal antibody is directed against a single epitope on the antigen. Monoclonal should not be construed to mean that it is necessary to generate antibodies in any particular way.
  • monoclonal antibodies useful in the present invention can be prepared by hybridoma methods as described in Kohler et al., Nature, 256: 495 (1975), or by recombinant DNA methods [see US Patent No. 4,816,567] can do.
  • monoclonal antibodies have been described, for example, in Clackson et al., Nature, 352: 624-628 (1991); Marks et al., J. Mol. Biol., 222: 581-597 (1991).
  • the term " antibody " includes the complete antibody form as well as antigen-binding fragments of the antibody molecule.
  • a complete antibody is a structure having two full-length light chains and two full-length heavy chains, each light chain linked by a disulfide bond with a heavy chain.
  • the heavy chain constant region has gamma (gamma), mu (mu), alpha (alpha), delta (delta) and epsilon (epsilon) types and subclasses gamma 1 (gamma 1), gamma 2 ), Gamma 4 (gamma 4), alpha 1 (alpha 1) and alpha 2 (alpha 2).
  • the constant region of the light chain has the kappa and lambda types (Cellular and Molecular Immunology, Wonsiewicz, MJ, Ed., Chapter 45, pp. 41-50, WB Saunders Co. Philadelphia, PA (1991); Nisonoff, A., Introduction to Molecular Immunology, 2nd Ed., Chapter 4, pp. 45-65, Sinauer Associates, Inc., Sunderland, MA (1984)).
  • Fabs in the antibody fragment have one antigen-binding site in a structure having a variable region of a light chain and a heavy chain, a constant region of a light chain, and a first constant region (C H1 ) of a heavy chain.
  • the F (ab ') 2 antibody is produced in which the cysteine residue of the hinge region of the Fab' forms a disulfide bond.
  • Fv is the smallest antibody fragment that has only the variable region of the heavy chain and the variable region of the light chain.
  • the two-chain Fv is a non-covalent linkage between the heavy chain variable region and the light chain variable region. Is generally linked to the variable region of the heavy chain and the variable region of the short chain through a peptide linker in a covalent bond or directly connected at the C-terminal to form a dimer-like structure like the double-chain Fv.
  • Such an antibody fragment can be obtained using a protein hydrolyzing enzyme (for example, a Fab can be obtained by restriction of the whole antibody to papain, and F (ab ') 2 fragment can be obtained by cleavage with pepsin), or Can be produced through recombinant DNA technology.
  • a protein hydrolyzing enzyme for example, a Fab can be obtained by restriction of the whole antibody to papain, and F (ab ') 2 fragment can be obtained by cleavage with pepsin
  • the antibody is in the form of a Fab or a complete antibody form.
  • the heavy chain constant region may be selected from any one of gamma (gamma), mu (mu), alpha (alpha), delta (delta) or epsilon (epsilon).
  • the light chain constant region may be kappa or lambda form, and according to one embodiment of the present invention is kappa type.
  • the term " heavy chain &quot refers to a variable region domain V H comprising an amino acid sequence having a sufficient variable region sequence to confer specificity to an antigen, and a variable region domain V H comprising three constant region domains C H1 , C H2 and C H3 Quot; means both the heavy chain and the fragment thereof.
  • the term " light chain " is used herein to refer to both the full length light chain comprising a variable region domain V L comprising an amino acid sequence having a sufficient variable region sequence for imparting specificity to an antigen and the constant region domain C L , it means.
  • CDR complementarity determining region
  • CDR complementarity determining region
  • the heavy and light chains each contain three CDRs (heavy chain (CDR H1 , CDR H2 and CDR H3 ) and light chains (CDR L1 , CDR L2 and CDR L3 )).
  • the CDR is an annular region involved in the recognition of an antigen, which is an important site in which the antibody provides an important contact moiety in binding to an antigen or epitope, and thus the specificity of the antibody to the antigen is determined as the sequence of the site changes .
  • framework region (FR) means a constituent element constituting a variable region of the antibody, and means a region located between the CDRs and serving to support the CDR ring structure do.
  • the antibody may comprise a light chain variable region represented by the amino acid sequence of SEQ ID NO: 7 or a heavy chain variable region represented by the amino acid sequence of SEQ ID NO: 8.
  • the antibody may be characterized by being represented by the amino acid sequence of SEQ ID NO: 9.
  • the double-target antibody or antigen-binding fragment thereof of the present invention may include variants of the amino acid sequence set forth in the Sequence Listing attached to SCF and galectin-1 in a specific manner.
  • the amino acid sequence of an antibody may be altered to improve the binding affinity and / or other biological properties of the antibody.
  • modifications include, for example, deletion, insertion and / or substitution of the amino acid sequence residues of the antibody.
  • amino acid variations are made based on the relative similarity of the amino acid side chain substituents, such as hydrophobicity, hydrophilicity, charge, size, and the like.
  • arginine, lysine and histidine are both positively charged residues; Alanine, glycine and serine have similar sizes; Phenylalanine, tryptophan and tyrosine have a similar shape.
  • arginine, lysine and histidine; Alanine, glycine and serine; And phenylalanine, tryptophan and tyrosine are biologically functional equivalents.
  • the hydropathic index of amino acids can be considered.
  • Each amino acid is assigned a hydrophobic index according to its hydrophobicity and charge: isoruicin (+4.5); Valine (+4.2); Leucine (+3.8); Phenylalanine (+2.8); Cysteine / cysteine (+2.5); Methionine (+1.9); Alanine (+1.8); Glycine (-0.4); Threonine (-0.7); Serine (-0.8); Tryptophan (-0.9); Tyrosine (-1.3); Proline (-1.6); Histidine (-3.2); Glutamate (-3.5); Glutamine (-3.5); Aspartate (-3.5); Asparagine (-3.5); Lysine (-3.9); And arginine (-4.5).
  • the hydrophobic amino acid index is very important in imparting the interactive biological function of proteins. It is known that substitution with an amino acid having a similar hydrophobicity index can retain similar biological activities. When the mutation is introduced with reference to the hydrophobic index, substitution is made between amino acids showing preferably a hydrophobic index difference of within ⁇ 2, more preferably within ⁇ 1, even more preferably within ⁇ 0.5.
  • hydrophilicity values are assigned to each amino acid residue: arginine (+3.0) ; Lysine (+3.0); Aspartate (+3.0 + -1); Glutamate (+3.0 + -1); Serine (+0.3); Asparagine (+0.2); Glutamine (+0.2); Glycine (0); Threonine (-0.4); Proline (-0.5 ⁇ 1); Alanine (-0.5); Histidine (-0.5); Cysteine (-1.0); Methionine (-1.3); Valine (-1.5); Leucine (-1.8); Isoru Isin (-1.8); Tyrosine (-2.3); Phenylalanine (-2.5); Tryptophan (-3.4).
  • the amino acid is substituted preferably within ⁇ 2, more preferably within ⁇ 1, even more preferably within ⁇ 0.5.
  • amino acid exchanges in proteins that do not globally alter the activity of the molecule are known in the art (H. Neurath, R. L. Hill, The Proteins, Academic Press, New York, 1979).
  • the most commonly occurring exchanges involve amino acid residues Ala / Ser, Val / Ile, Asp / Glu, Thr / Ser, Ala / Gly, Ala / Thr, Ser / Asn, Ala / Val, Ser / Gly, Thy / Pro, Lys / Arg, Asp / Asn, Leu / Ile, Leu / Val, Ala / Glu and Asp / Gly.
  • the double target antibody specifically binding to the SCF and galectin-1 of the present invention may be characterized by including a human IgG1-derived constant region.
  • the present invention provides a 3C4 antibody which is a dual target antibody which further comprises a human IgG1-derived constant region in the light chain variable region and the heavy chain variable region.
  • the double target antibody of the present invention is preferably a "humanized antibody ".
  • humanized antibody is meant an antibody consisting of an amino acid sequence derived from a human germline, some or all, by altering the sequence of the antibody bearing the non-human complementarity determining region (CDR). More preferably, the antibody of the invention may be a " human antibody ".
  • the term " human antibody &quot broadly refers to antibodies comprising variable regions (CDRs and FRs) derived from human immunoglobulins, and to a lesser extent human immunoglobulins Quot; means an antibody comprising a derived variable region and a constant region.
  • the human antibody may be in the form of a whole antibody as well as a functional fragment of an antibody molecule. Human antibodies can be prepared using a variety of techniques known in the art.
  • the immunization reaction is less likely to occur than the conventional humanized antibody or mouse antibody, and thus there is an advantage that an undesired immune response does not occur when administered to a human. And can be very useful as an antibody for therapeutic use.
  • the human antibody can be regarded as a dual target antibody that specifically binds to the SCF and galectin-1 of the invention, wherein the human antibody specifically binds to SCF and galectin- And galectin-1-induced neovascularization, but the present invention is not particularly limited thereto.
  • the human antibody may be glycosylated and / or pegylated to enhance the residence time in a living body.
  • glycosylation of the present invention means a processing method in which a glycosyl group is transferred to a protein.
  • the glycation is carried out by a glycosyltransferase in which a glycosyl group is bonded to a serine, threonine, asparagine or hydrosilicon residue of a target protein.
  • the glycated protein can be used not only as a constituent material of a living tissue, It also plays an important role in cell recognition on the surface. Therefore, in the present invention, the effect of the human antibody can be improved by changing the pattern of glycation or glycation of the human antibody.
  • PEGylation of the present invention means a processing method for improving the blood residence time of the human antibody by introducing polyethylene glycol into the human antibody (Anna M. Wu, et al., Nature Biotechnology, Drug Discovery, 5: 147-159, 2006; Alain Beck, et al., Immunology, 10: 345-352, 2010).
  • the hydrophilicity of the surface of the nanoparticles is increased, and the immune function including macrophages in the human body, which predominates and extinguishes pathogens, waste materials, Rapid dissolution in the body through a so-called stealth effect that prevents recognition from the body can be prevented.
  • the pegylation used in the present invention can be formed by a method of forming an amide group by bonding of a carboxyl group of hyaluronic acid and an amine group of polyethylene glycol. However, it is not limited thereto and pegylation can be carried out in various ways.
  • the polyethylene glycol to be used is not particularly limited, but preferably has a molecular weight of 100-1,000 and has a linear or branched structure.
  • the saccharification and / or pegylation may be modified by known methods in the art so long as the function of the antibody of the present invention is maintained.
  • the human antibody of the present invention may be modified by various saccharification and / Or mutant human antibodies in which the pegylation pattern is modified.
  • the present invention also provides a method for producing a light chain CDR1 comprising the light chain CDR1 represented by SEQ ID NO: 1, the light chain CDR2 represented by SEQ ID NO: 2, and the light chain CDR3 represented by SEQ ID NO: 3 by the nucleotide sequence of SEQ ID NO: 10, SEQ ID NO: 11 and SEQ ID NO: DNA encoding a light chain variable region comprising; And a heavy chain variable region comprising the nucleotide sequence of SEQ ID NO: 13, SEQ ID NO: 14 and SEQ ID NO: 15, which respectively encode the heavy chain CDR1 of SEQ ID NO: 4, the heavy chain CDR2 of SEQ ID NO: 5 and the heavy chain CDR3 of SEQ ID NO: DNA coding region; A DNA encoding a double-target antibody that specifically binds to SCF and galectin-1.
  • the DNA encoding the light chain variable region may be characterized by being represented by SEQ ID NO: 16.
  • the DNA encoding the heavy chain variable region may be characterized by being represented by SEQ ID NO: 17.
  • the DNA encoding the double-target antibody may be characterized by being represented by SEQ ID NO: 18.
  • the antibody of the present invention or the nucleic acid molecule encoding the same is interpreted as including a sequence showing substantial identity with the sequence described in the sequence listing.
  • the above substantial identity is obtained by aligning the sequence of the present invention with any other sequence as much as possible and analyzing the aligned sequence using algorithms commonly used in the art, Homology, more preferably 70% homology, even more preferably 80% homology, and most preferably 90% homology. Alignment methods for sequence comparison are known in the art.
  • nucleic acid molecule &quot is meant to encompass both DNA (gDNA and cDNA) and RNA molecules.
  • Nucleotides that are basic building blocks in nucleic acid molecules include not only natural nucleotides, analogue).
  • the nucleic acid molecule sequences encoding the heavy chain variable region and the light chain variable region of the present invention may be modified. Such modifications include addition, deletion or non-conservative substitution or conservative substitution of nucleotides.
  • Nucleic acid molecules of the invention that encode the dual target antibodies of the invention are also contemplated to include nucleotide sequences that exhibit substantial identity to the nucleotide sequences described above.
  • the above substantial identity can be determined by aligning the nucleotide sequence of the present invention with any other sequence as much as possible and analyzing the aligned sequence using algorithms commonly used in the art to obtain 80% Or 95% homology with the nucleotide sequence of SEQ ID NO: 1.
  • the present invention also provides a vector comprising the DNA and a cell transformed with the vector.
  • &quot refers to a plasmid vector as a means for expressing a gene of interest in a host cell; Cosmeptide vector; And viral vectors such as bacteriophage vectors, adenovirus vectors, retroviral vectors, and adeno-associated viral vectors.
  • the DNA encoding the dual target antibody in the vector of the present invention may be operatively linked to a promoter.
  • &quot operably linked " means a functional linkage between a nucleic acid expression control sequence (e.g., an array of promoter or transcription factor binding sites) and another nucleic acid sequence, Thereby controlling the transcription and / or translation of the different nucleic acid sequences.
  • a nucleic acid expression control sequence e.g., an array of promoter or transcription factor binding sites
  • the recombinant vector system of the present invention can be constructed through various methods known in the art and can typically be constructed as a vector for cloning or as a vector for expression.
  • the vector of the present invention can be constructed by using prokaryotic cells or eukaryotic cells as hosts.
  • the expression vector of the present invention may include an antibiotic resistance gene commonly used in the art as a selection marker, and the antibiotic resistance gene may be selected from the group consisting of ampicillin, gentamycin, carbenicillin, chloramphenicol, streptomycin, kanamycin Neotymine, neomycin, and tetracycline.
  • the cells may be bacteria or animal cells.
  • the cells transformed with the above-mentioned vector are host cells capable of continuously cloning and expressing the vector of the present invention stably, and any host cell known in the art can be used.
  • suitable eukaryotic host cells of the vector may be selected from the group consisting of monkey kidney cells (COS7), NSO cells, SP2 / 0, Chinese hamster ovary (CHO) cells, W138, baby hamster kidney cells, MDCK, myeloma cell lines, HuT 78 cells and HEK-293 cells, preferably CHO cells, but are not limited thereto.
  • the present invention also provides a pharmaceutical composition for preventing or treating an angiogenesis-related disease comprising a double-target antibody that specifically binds to SCF and galectin-1 of the present invention.
  • the pharmaceutical composition of the present invention uses the above-mentioned double-target antibody or antigen-binding fragment thereof of the present invention as an active ingredient, the content common to both of them is that, in order to avoid the excessive complexity of the present specification by the repeating substance, .
  • the angiogenesis-related disease refers to a disease caused by the formation of blood vessels.
  • the intraocular-vessel-related diseases include macular degeneration, age-related macular degeneration, diabetic retinopathy, choroidal neovascularization, glaucoma Retinopathy of prematurity, glaucoma, corneal dystrophy, and retinoschisis, and preferably retinopathy of prematurity, retinopathy of prematurity, retinopathy of prematurity, retinopathy of prematurity, retinopathy of prematurity, retinopathy of prematurity, retinopathy of prematurity, Lt; / RTI >
  • the dual target antibodies of the present invention can inhibit angiogenesis of vascular endothelial cells, and are effective for the prevention or treatment of angiogenesis-related diseases.
  • the pharmaceutically acceptable carriers to be contained in the pharmaceutical composition of the present invention are those conventionally used in the present invention and include lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, But are not limited to, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrups, methylcellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil. It is not.
  • the pharmaceutical composition of the present invention may further contain a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc., in addition to the above components.
  • a lubricant e.g., a lubricant, a wetting agent, a sweetening agent, a flavoring agent, an emulsifying agent, a suspending agent, a preservative, etc.
  • Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).
  • the pharmaceutical composition of the present invention may be administered parenterally and may be administered, for example, by intravenous infusion, subcutaneous injection, muscle injection, intraperitoneal injection, topical administration, intranasal administration, intrapulmonary administration and rectal administration.
  • the appropriate dosage of the pharmaceutical composition of the present invention varies depending on factors such as the formulation method, the administration method, the age, body weight, sex, pathological condition, food, administration time, administration route, excretion rate and responsiveness of the patient, Usually, a skilled physician can readily determine and prescribe dosages effective for the desired treatment or prophylaxis.
  • the daily dosage of the pharmaceutical composition of the present invention may be 0.0001-100 mg / kg.
  • the term "pharmaceutically effective amount” means an amount sufficient to prevent or treat an angiogenesis-related disorder.
  • the pharmaceutical composition of the present invention may be formulated into a unit dosage form by using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by those having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container.
  • the formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, suppositories, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.
  • composition of the present invention can be used in combination with or in combination with other therapeutic agents targeting VEGF, and thus there may be synergistic effects such as more effective inhibition of abnormal angiogenesis.
  • the therapeutic agent targeting VEGF may be, but is not limited to, eilea, Aafibercept or lucentis (Ranibizumab).
  • the present invention also relates to a method for the treatment of SCF and galectin-1 comprising administering to a subject in need thereof a double-target antibody specifically binding to SCF and galectin-1 according to the present invention; And a method for preventing or treating an angiogenesis-related disease.
  • the subject is preferably a mammal, including a human, and is a patient in need of treatment for an angiogenesis-related disease, a patient undergoing treatment for angiogenesis-related diseases, a patient suffering from an angiogenesis-related disease, And patients who underwent surgical procedures for the treatment of angiogenesis-related diseases may also be included.
  • angiogenesis-related diseases can be alleviated or treated.
  • &quot alleviation " refers to any action that alleviates or benefits an angiogenesis-related disorder by administration of a pharmaceutical composition in accordance with the present invention.
  • the pharmaceutical composition of the present invention is administered in a pharmaceutically effective amount.
  • the pharmaceutical composition for preventing or treating angiogenesis-related diseases comprising a double-target antibody specifically binding to SCF and galectin-1 according to the present invention can be used as a medicament for the treatment of other angiogenesis- And can be simultaneously / sequentially processed.
  • Such administration may be single or multiple administrations. It is important to take into account all of the above factors and to administer the amount in which the maximum effect can be obtained in a minimal amount without adverse effect, and can be easily determined by those skilled in the art.
  • the present invention also relates to a method for the treatment of SCF and galectin-1 comprising administering to a subject in need thereof a double-target antibody specifically binding to SCF and galectin-1 according to the present invention; A method for inhibiting angiogenesis.
  • the method relates to a method of inhibiting SCF and galectin-1-induced angiogenesis by simultaneously neutralizing galectin-1 as well as SCF.
  • This method inhibits c-kit phosphorylation by SCF and inhibits phosphorylation of AKT and ERK, the down-stream signaling pathways, resulting in the tube formation of SCF and galectin-1-induced vascular endothelial cells It can be a method of effectively suppressing the effect.
  • the present invention also provides a composition for simultaneous detection of SCF and galectin-1 comprising dual target antibodies specifically binding to SCF and galectin-1 according to the present invention, and a kit comprising said composition.
  • the detection composition and kit of the present invention include the double-target antibody or antigen-binding fragment thereof of the present invention described above, and it is possible to simultaneously detect the binding specifically to SCF and galectin-1.
  • the detection composition and kit of the present invention include an antibody
  • they can be basically prepared for various immunoassays or immunostaining.
  • the immunoassay or immunostaining can be carried out by radioimmunoassay, radioimmunoprecipitation, immunoprecipitation, enzyme-linked immunosorbent assay (ELISA), capture-ELISA, inhibition or competition assay, sandwich assay, flow cytometry, But are not limited to, immunoaffinity purification.
  • Samples that can be applied to the detection composition and kit of the present invention include, but are not limited to, cell, tissue or tissue-derived extract, lysate or purified water, blood, plasma, serum, lymph or ascites.
  • the emulsion was prepared by mixing 50 ug of the recombinant SCF (Stem Cell Factor) protein (cat # 7466-SC) purchased from R & D systems with the same volume of Freund's Adjuvant (Sigma, USA) standard). The emulsion was injected into the abdominal cavity of 4 humanized NSG mice prepared by 7-week-old female human CD34 + cell injection. Then, each mouse was injected with 50 ⁇ ⁇ of antigen into a total volume of 500 ⁇ ⁇ to induce antibody production. After one week and two weeks thereafter, an emulsion mixed with an incomplete Prunts Ajvant (Sigma, USA) and an antigen, respectively, was injected into the abdominal cavity of the mice.
  • Blood was collected from the eye of the immunized mouse through the above method and placed in a 1.5 ml microcentrifuge tube and centrifuged at 13,000 rpm for 10 minutes. Serum was separated and stored at -20 ° C until experiments to confirm antibody formation were performed. Enzyme immunoassay using an antigen protein was performed to confirm whether or not an antibody had been generated. Then, three days before the cell fusion, an emulsion prepared by mixing incomplete Pronto Ajvant (Sigma, USA) and an antigen was injected into the abdominal cavity of a mouse.
  • mice were sacrificed to isolate spleen cells and fused with myeloma cells P3X63Ag8.653 (ATCC CRL-1580) to prepare hybridomas.
  • P3X63Ag8.653 cells of the mice were cultured in a culture plate using RPMI1640 medium supplemented with 10% fetal bovine serum.
  • P3X63Ag8.653 cells were washed twice with serum-free RPMI1640 medium (Hyclone, USA) and adjusted to a concentration of 1 ⁇ 10 7 cells.
  • Mice were sacrificed by cervical dislocation and the spleens were collected and then placed in a mesh vessel (Sigma, USA) to separate the cells. After preparing a suspension of splenocytes, the suspension was washed with centrifugation.
  • the spleen cell solution was exposed to Tris-NH 4 Cl (Tris 20.6 g / L, NH 4 Cl 8.3 g / L) to lyse red blood cells.
  • Tris-NH 4 Cl Tris 20.6 g / L, NH 4 Cl 8.3 g / L
  • the completely separated antibody-producing cells were centrifuged at 400 xg for 5 minutes, washed twice in serum-free medium and resuspended in 10 ml medium. Lymphocytes were counted using a hemocytometer and 1 x 10 8 of lymphocytes were mixed with 1 x 10 (10: 1) of P3X63Ag 8.653 cells in serum-free medium. The centrifugation was carried out at 400 xg for 5 minutes. Then, 1 ml of 50% (M / V) polyethylene glycol 1500 (Sigma, USA) warmed at 37 ° C) was slowly added for 1 minute and mixed.
  • the fusion mixture prepared above was diluted with serum-free RPMI 1640 and centrifuged at 400 xg for 3 minutes.
  • Cells were suspended in 35 ml of RPMI 1640 selection medium supplemented with 20% fetal bovine serum and HAT (100 uM hypoxanthine, 0.4 uM aminopterin, 16 uM thymidine).
  • HAT 100 uM hypoxanthine, 0.4 uM aminopterin, 16 uM thymidine.
  • 100ul of the suspension was loaded on a 96-well plate coated with feeder cells (macrophages separated from abdominal cavity using RPMI1640) 1 day ago and cultured at 37 ⁇ ⁇ and 5% CO 2 .
  • the HAT medium was replaced every 2-3 days and the cells were cultured for 14 days.
  • RPMI1640 medium supplemented with 20% fetal bovine serum and HT (medium in which 0.4 uM aminopterin was removed from HAT) was replaced and secondary cultured.
  • the supernatants of the hybridoma colonies prepared in Examples 1-3 were collected and subjected to enzyme immunoassay to confirm the production of antibodies specific to the antigen produced.
  • the culture medium of the fusion cells showing a proper concentration of 4 times or more as compared with the negative control was selected, and the culture was transferred to a 24-well culture plate.
  • the cells were cultured by limiting dilution so that one cell was contained per well in a 96-well plate, and the culture was recovered. Then, the SCF protein used as an antigen was coated on the 96-well plate at 0.1 ug / well, and enzyme immunoassay was performed.
  • an optical density (OD value) was measured at a wavelength of 450 nm to finally select fusion cells producing 9 monoclonal antibodies (3C6, 3A2, 3C3, 3A4, 3E7, 3C8, 3C4, 3F7 and 3F3) . This is shown in FIG.
  • variable region specific primers For the cDNA obtained by the reverse transcription reaction, the corresponding regions of the light and heavy chains of the antibody were amplified using variable region specific primers.
  • the primers used are shown in Table 1 below.
  • the kappa light chain domain was amplified from cDNA using the primers shown in SEQ ID NOS: 1 and 2.
  • the amplified DNA was confirmed by agarose gel electrophoresis and the results are shown in FIG.
  • the IgG1 heavy chain domain was amplified from cDNA using the primers shown in SEQ ID NOS: 3 and 4.
  • the amplified DNA was confirmed by agarose gel electrophoresis, and the results are shown in FIG.
  • the light chain of 3C4 includes CDR1 (SEQ ID NO: 1), CDR2 (SEQ ID NO: 2) and CDR3 (SEQ ID NO: 3) of the light chain in blue letter order, (SEQ ID NO: 4), CDR2 (SEQ ID NO: 5) and CDR3 (SEQ ID NO: 6) of the heavy chain in order of blue letters.
  • the light chain amino acid sequence of 3C4 is shown in SEQ ID NO: 7
  • the heavy chain amino acid sequence is shown in SEQ ID NO: 8
  • the entire amino acid sequence of 3C4 is shown in SEQ ID NO:
  • the light chain (SEQ ID NO: 16) and heavy chain (SEQ ID NO: 17) base sequences of 3C4 are shown in Table 2, and the whole nucleotide sequence of 3C4 is shown in SEQ ID NO:
  • variable domain of the anti-SCF antibody 3C4 (hereinafter 3C4) obtained in Example 3 was grafted to a human Fc amino acid sequence and cloned into a pCHO vector (lifetechnology).
  • the light chain variable domain was fused within the frame for the human kappa constant region and the heavy chain variable domain was fused within the frame for the human IgG1 constant region.
  • the leader peptide sequence for secretion of the full length IgG1 antibody into the medium was added to the two genes and the gene was synthesized and verified again by sequencing.
  • Three clones were selected for expression testing in CHO cells. Glycerol stocks were prepared for three clones and plasmid DNA without endotoxin was prepared for expression testing in CHO cells.
  • the plasmid DNA obtained in Example 4 was transfected into CHO-S cells.
  • CHO-S Invitrogen, 10743-029
  • DMEM fetal calf serum
  • the cells were dispensed and DNA-lipofectamine complexes were prepared for the transfected samples.
  • the cells were incubated overnight at 37 ° C in 5% CO 2 in the incubator. After incubation for one week with adding the medium once every 2-3 days, the culture was recovered and bound to Protein A / G agarose (company) And washed with PBS.
  • SDS-PAGE showed that a heavy chain of about 50 kDa and a light chain band of about 25 kDa were observed. Thus, it was confirmed that the antibody was correctly synthesized and produced.
  • the K D value was about 18.8 ⁇ 2 ⁇ 10 -9 M, confirming that the 3C4 antibody of the present invention showed a strong affinity for SCF.
  • the 3C4 antibody of the present invention effectively inhibited the tube formation of HUVEC induced by SCF. From the above results, it was confirmed that the 3C4 antibody of the present invention can be used for preventing or treating angiogenesis-related diseases by inhibiting angiogenesis.
  • the 3C4 antibody of the present invention not only inhibits c-kit phosphorylation by SCF by effectively neutralizing SCF but also affects the down-stream signaling pathway, resulting in phosphorylation of AKT and ERK Respectively.
  • Protein microarray analysis was performed using a HuProt TM v3.1 human proteome microarray (CDI laboratories) protein chip.
  • the protein chip was blocked with PBST (pH 7.4) containing 2% BSA and 0.1% Tween 20 at room temperature for 2 hours.
  • PBST pH 7.4
  • biotinylated 3C4 antibody was dissolved in PBST (pH 7.4) containing 2% BSA and 0.1% Tween 20, followed by binding at 4 ° C for 8 hours, followed by washing three times with PBST.
  • the 3C4 antibody of the present invention shows a high binding force against Galectin-1 (LGALS1) in addition to SCF.
  • the K D value was about 46.9 ⁇ 9 ⁇ 10 -9 M, confirming that the 3C4 antibody of the present invention showed strong affinity for galectin-1 as well as SCF.
  • VEGF Vascular endothelial growth factor
  • SCF Stem Cell Factor
  • galectin-1 vascular endothelial growth factor-1

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

La présente invention concerne un anticorps à double ciblage ciblant le facteur de croissance des cellules souches (SCF) et la galectine-1 et une composition destinée à prévenir ou traiter des maladies associées à l'angiogenèse le comprenant. La présente invention concerne un anticorps à double ciblage dérivé d'un anticorps monoclonal humain qui peut inhiber efficacement l'angiogenèse par neutralisation simultanée du SCF et de la galectine-1 impliqués dans l'angiogenèse, et une composition pharmaceutique destinée à prévenir ou à traiter des maladies liées à l'angiogenèse comprenant ledit anticorps. L'anticorps à double ciblage selon la présente invention peut efficacement prévenir ou traiter des maladies liées à l'angiogenèse par neutralisation simultanée de deux cibles impliquées dans l'angiogenèse, où les maladies liées à l'angiogenèse provoquent une hémorragie due à des vaisseaux sanguins soumis à changement en raison d'une angiogenèse anormale qui augmente ainsi leur perméabilité.
PCT/KR2018/013016 2017-10-31 2018-10-30 Anticorps à double ciblage ciblant le scf et la galectine-1 et son utilisation Ceased WO2019088658A1 (fr)

Priority Applications (4)

Application Number Priority Date Filing Date Title
CN201880070926.4A CN111295393B (zh) 2017-10-31 2018-10-30 靶向干细胞因子及半乳糖凝集素-1的双重靶向抗体及其用途
EP18873464.4A EP3712169A4 (fr) 2017-10-31 2018-10-30 Anticorps à double ciblage ciblant le scf et la galectine-1 et son utilisation
US16/760,513 US11377489B2 (en) 2017-10-31 2018-10-30 Dual-targeting antibody targeting SCF and galectin-1 and use thereof
JP2020543441A JP6922098B2 (ja) 2017-10-31 2018-10-30 Ｓｃｆ及びガレクチン−１を標的とする二重標的抗体及びその用途

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
KR10-2017-0143816 2017-10-31
KR20170143816 2017-10-31
KR1020180127615A KR102131898B1 (ko) 2017-10-31 2018-10-24 Scf 및 갈렉틴-1을 표적으로 하는 이중표적항체 및 그 용도
KR10-2018-0127615 2018-10-24

Publications (1)

Publication Number Publication Date
WO2019088658A1 true WO2019088658A1 (fr) 2019-05-09

Family

ID=66332155

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/013016 Ceased WO2019088658A1 (fr) 2017-10-31 2018-10-30 Anticorps à double ciblage ciblant le scf et la galectine-1 et son utilisation

Country Status (1)

Country Link
WO (1) WO2019088658A1 (fr)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022197914A3 (fr) * 2021-03-17 2022-10-27 Opsidio, LLC Anticorps anti-facteur de cellules souches et leurs méthodes d'utilisation
US12410246B2 (en) 2019-09-16 2025-09-09 Opsidio, LLC Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20110142840A1 (en) * 2008-05-21 2011-06-16 Oncomed Pharmaceuticals, Inc Compositions and Methods for Diagnosing and Treating Cancer
US20130011409A1 (en) * 2009-11-13 2013-01-10 Consejo Nactional De Investigaciones Cientificias Y Tecnicas Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
WO2015173756A2 (fr) * 2014-05-16 2015-11-19 Pfizer Inc. Anticorps bispécifiques
WO2016141387A1 (fr) * 2015-03-05 2016-09-09 Xencor, Inc. Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
US20170073395A1 (en) * 2015-05-18 2017-03-16 Pfizer Inc. Humanized antibodies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US20110142840A1 (en) * 2008-05-21 2011-06-16 Oncomed Pharmaceuticals, Inc Compositions and Methods for Diagnosing and Treating Cancer
US20130011409A1 (en) * 2009-11-13 2013-01-10 Consejo Nactional De Investigaciones Cientificias Y Tecnicas Compositions, Kits, and Methods for the Diagnosis, Prognosis, Monitoring, Treatment and Modulation of Post-Transplant Lymphoproliferative Disorders and Hypoxia Associated Angiogenesis Disorders Using Galectin-1
WO2015173756A2 (fr) * 2014-05-16 2015-11-19 Pfizer Inc. Anticorps bispécifiques
WO2016141387A1 (fr) * 2015-03-05 2016-09-09 Xencor, Inc. Modulation de lymphocytes t avec des anticorps bispécifiques et des hybrides fc
US20170073395A1 (en) * 2015-05-18 2017-03-16 Pfizer Inc. Humanized antibodies

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
"Cellular and Molecular Immunology", 1991, WB SAUNDERS CO. PHILADELPHIA, pages: 41 - 50
"Remington's Pharmaceutical Sciences", 1995
ALAIN BECK ET AL., IMMUNOLOGY, vol. 10, 2010, pages 345 - 352
ANNA M. WU ET AL., NATURE BIOTECHNOLOGY, vol. 23, no. 9, 2005, pages 1137 - 1146
CLACKSON ET AL., NATURE, vol. 352, 1991, pages 624 - 628
DAVID SCHRAMA ET AL., DRUG DISCOVERY, vol. 5, 2006, pages 147 - 159
H. NEURATHR. L. HILL: "The Proteins", 1979, ACADEMIC PRESS
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1987, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
KOHLER ET AL., NATURE, vol. 256, 1975, pages 495
MARKS ET AL., J. MOL. BIOL., vol. 222, 1991, pages 581 - 597
NISONOFF, A.: "Introduction to Molecular Immunology", 1984, SINAUER ASSOCIATES, INC., pages: 45 - 65
See also references of EP3712169A4 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12410246B2 (en) 2019-09-16 2025-09-09 Opsidio, LLC Anti-stem cell factor antibodies and methods of blocking the interaction between SCF and c-Kit
WO2022197914A3 (fr) * 2021-03-17 2022-10-27 Opsidio, LLC Anticorps anti-facteur de cellules souches et leurs méthodes d'utilisation

Similar Documents

Publication Publication Date Title
WO2020076105A1 (fr) Nouvel anticorps anti-c-kit
WO2020111913A1 (fr) Anticorps anti-4-1bb et son utilisation
WO2019098682A1 (fr) Anticorps anti-her2 ou fragment de liaison à l'antigène de celui-ci, et récepteur antigénique chimérique le comprenant
WO2017052241A1 (fr) Nouvel anticorps anti-mésothéline et composition le comprenant
WO2015005632A1 (fr) Nouvelles protéines à double cible se liant spécifiquement à dll4 et vegf et leur utilisation
WO2014119969A1 (fr) Anticorps anti-c5 et méthode de prévention et de traitement de maladies liées au complément
WO2019004799A1 (fr) Conjugué de protéine de vegf-grab et de médicament, et son utilisation
WO2012165925A2 (fr) Anticorps anti-c-met présentant une activité hgf et son utilisation
WO2019112347A2 (fr) Anticorps ou son fragment de liaison à l'antigène pour reconnaître spécifiquement une malignité de cellule b, récepteur d'antigène chimérique le comprenant, et son utilisation
WO2021091359A1 (fr) Épitope d'antigène de surface de lymphocyte t régulateur, et anticorps se liant de manière spécifique à celui-ci
WO2020005003A1 (fr) Anticorps monoclonal se liant de manière spécifique à lag-3 et son utilisation
WO2022169269A1 (fr) Anticorps anti-ctla-4 et son utilisation
WO2022030730A1 (fr) Récepteur antigénique chimérique anti-mésothéline se liant de manière spécifique à la mésothéline
WO2019235856A1 (fr) Anticorps se liant à tie2 et son utilisation
WO2019216675A1 (fr) Épitope d'antigène de surface de lymphocyte t régulateur et anticorps se liant de manière spécifique à celui-ci
WO2019088658A1 (fr) Anticorps à double ciblage ciblant le scf et la galectine-1 et son utilisation
WO2020004934A1 (fr) Anticorps anti-bcma et utilisation associée
WO2023043123A1 (fr) Variants fc glycosylés ayant une affinité de liaison sélective améliorée à fcγriiia
US11377489B2 (en) Dual-targeting antibody targeting SCF and galectin-1 and use thereof
WO2021029746A2 (fr) Anticorps anti-tie 2 et son utilisation
WO2017074013A1 (fr) Anticorps destiné à être réticulé à la sema3a humaine et de souris, et son utilisation
WO2020246760A1 (fr) Anticorps anti-oscar pour la prévention ou le traitement de l'arthrose
WO2020141869A1 (fr) Anticorps se liant de manière spécifique à icam-1 et utilisation associée
WO2023182866A1 (fr) Anticorps spécifique de hla-g et son utilisation
WO2019093807A2 (fr) Anticorps se liant spécifiquement à il-17a et son utilisation

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 18873464

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2020543441

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2018873464

Country of ref document: EP

Effective date: 20200602